[Latest Drug Therapies for Cervical Cancer]

Cervical cancer remains a major global health burden, with limited therapeutic outcomes in advanced and recurrent settings. For locally advanced disease, cisplatin-based chemoradiotherapy(CRT)has long been the standard of care; however, the advent of immune checkpoint inhibitors(ICIs)and antibody-drug conjugates(ADCs)has recently reshaped the treatment landscape. The phase Ⅲ KEYNOTE-826 trial demonstrated that pembrolizumab combined with chemotherapy significantly improved overall survival(OS)in recurrent or metastatic cervical cancer, establishing a new first-line standard. Moreover, the KEYNOTE-A18 trial showed that pembrolizumab in combination with CRT followed by maintenance therapy achieved a 36-month OS rate of 82.6%, marking the first major breakthrough in locally advanced disease in approximately 25 years. In parallel, the ADC tisotumab vedotin significantly prolonged OS to 11.5 months in previously treated recurrent or metastatic cases in the phase Ⅲ innovaTV 301 trial and received approval in Japan in March 2025. Current guidelines, including NCCN v1, 2025 and the ESMO/ESGO/ESTRO joint recommendations, endorse ICI-combined CRT for locally advanced disease, ICI plus chemotherapy as first-line treatment for recurrent/metastatic disease, and ADC therapy as the standard second-line option, reflecting a global reorganization of therapeutic algorithms. Future directions include the establishment of predictive biomarkers, deeper understanding of the tumor microenvironment, and optimization of ICI-ADC combination strategies, aiming to realize a personalized treatment paradigm grounded in immune and molecular targeting.